Guillaume Andrieu PhD and Jordan Shafran report research on new mechanisms to develop immunotherapy for triple negative breast cancer
The research team of Andrieu and Shafran, directed by Gerald Denis PhD, in the BU-BMC Cancer Center, has just reported that “BET bromodomain targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response”, which appeared today in Cell Reports ‘Sneak Peek’ https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3260754
The mechanisms that control the expression of immune inhibitory molecules in diverse cancer types, such as PD-L1, and host immune receptors such as PD-1 on T cells in the tumor microenvironment, are being investigated urgently. New tools to inhibit these checkpoints show great promise to unleash anti-tumor immunity, and results of recent cancer clinical trials are encouraging. Immunotherapy as an exciting and evolving field was recognized on October 1, 2018, with the award of the Nobel Prize in Medicine to Honjo and Allison. On the other hand, clinical cases in which immune therapy approaches fail are poorly understood, and failure is common enough for certain cancer types to have caused widespread frustration in clinical trials. Given the limited therapeutic options available to patients with triple negative breast cancer, new modalities are urgently needed, and promising results from new immunotherapy clinical trials could quickly reshape the treatment of this subtype of breast cancer.
Here, Andrieu, Shafran and Denis show that inhibition of the BET bromodomain protein family can reduce PD-L1 expression in cellular models of triple negative breast cancer. It is also highly innovative and significant that they show these same pathways control PD-1 expression in human primary T cells, which holds out the possibility that multiple relevant cells in the tumor microenvironment could be targeted by these approaches. They are continuing this research, with support from the National Cancer Institute with a new grant, called “BET bromodomain proteins and the immunometabolism of triple negative breast cancer” (R01 CA222170).
Shuaiying Cui, Ph.D, Promoted to Associate Professor of Medicine
We are pleased to announce that Shuaiying Cui, Ph.D, has been promoted to the rank of Associate Professor of Medicine in the Section of Hematology and Medical Oncology. Dr. Cui received his Ph.D. in Genetics at the University of Science and Technology of China and completed post-doctoral research fellowships in the laboratories of Yi Zhang and James Engel at the University of Michigan. He was recruited to Boston University and Boston Medical Center in 2016, where his work on elucidating new mechanisms for the induction of fetal hemoglobin has gained significant international attention. In 2019, Dr Cui received a prestigious Doris Duke Sickle Cell Disease/Advancing Cures Award, putting him in the company of a select group of high-profile national investigators in the field of red blood cell disorders. In 2022, Dr. Cui received an R01 grant for his work targeting PGC1-alpha as a potential treatment for sickle cell disease. Dr. Cui’s research contributions have important scientific and therapeutic implications; we congratulate him on his promotion!